134 related articles for article (PubMed ID: 37831945)
1. Reactive Oxygen Species-Sensitive Biodegradable Mesoporous Silica Nanoparticles Harboring TheraVac Elicit Tumor-Specific Immunity for Colon Tumor Treatment.
Huang Y; Nahar S; Alam MM; Hu S; McVicar DW; Yang D
ACS Nano; 2023 Oct; 17(20):19740-19752. PubMed ID: 37831945
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel modified vaccine (TheraVac
Masud Alam M; Huang Y; Oppenheim JJ; Yang D
Cytokine; 2023 Sep; 169():156270. PubMed ID: 37302280
[TBL] [Abstract][Full Text] [Related]
3. A Therapeutic Vaccine in Combination with Cyclic GMP-AMP Cures More Differentiated Melanomas in Mice.
Alam MM; Gower T; Jiang M; Oppenheim JJ; Yang D
J Immunol; 2023 May; 210(9):1428-1436. PubMed ID: 36947147
[TBL] [Abstract][Full Text] [Related]
4. Temperature-sensitive copolymer-coated fluorescent mesoporous silica nanoparticles as a reactive oxygen species activated drug delivery system.
Yu F; Wu H; Tang Y; Xu Y; Qian X; Zhu W
Int J Pharm; 2018 Jan; 536(1):11-20. PubMed ID: 29146540
[TBL] [Abstract][Full Text] [Related]
5. Mesoporous Silica Nanoparticles as pH-Responsive Carrier for the Immune-Activating Drug Resiquimod Enhance the Local Immune Response in Mice.
Wagner J; Gößl D; Ustyanovska N; Xiong M; Hauser D; Zhuzhgova O; Hočevar S; Taskoparan B; Poller L; Datz S; Engelke H; Daali Y; Bein T; Bourquin C
ACS Nano; 2021 Mar; 15(3):4450-4466. PubMed ID: 33648336
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic vaccine to cure large mouse hepatocellular carcinomas.
Han Z; Yang D; Trivett A; Oppenheim JJ
Oncotarget; 2017 Aug; 8(32):52061-52071. PubMed ID: 28881713
[TBL] [Abstract][Full Text] [Related]
7. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
[TBL] [Abstract][Full Text] [Related]
8. Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors.
Nie Y; Yang D; Trivett A; Han Z; Xin H; Chen X; Oppenheim JJ
Sci Rep; 2017 Oct; 7(1):14186. PubMed ID: 29079801
[TBL] [Abstract][Full Text] [Related]
9. A Dual Concentration-Tailored Cytokine-Chemo Nanosystem to Alleviate Multidrug Resistance and Redirect Balance of Cancer Proliferation and Apoptosis.
Hsia Y; Sivasubramanian M; Chu CH; Chuang YC; Lai YK; Lo LW
Int J Nanomedicine; 2023; 18():4253-4274. PubMed ID: 37534057
[TBL] [Abstract][Full Text] [Related]
10. Effects of Skeleton Structure of Mesoporous Silica Nanoadjuvants on Cancer Immunotherapy.
Tan J; Ding B; Chen H; Meng Q; Li J; Yang C; Zhang W; Li X; Han D; Zheng P; Ma P; Lin J
Small; 2024 Jan; 20(3):e2305567. PubMed ID: 37702141
[TBL] [Abstract][Full Text] [Related]
11. Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold.
Nguyen TL; Cha BG; Choi Y; Im J; Kim J
Biomaterials; 2020 May; 239():119859. PubMed ID: 32070828
[TBL] [Abstract][Full Text] [Related]
12. Efficacy-shaping nanomedicine by loading Calcium Peroxide into Tumor Microenvironment-responsive Nanoparticles for the Antitumor Therapy of Prostate Cancer.
Wu D; Zhu ZQ; Tang HX; Shi ZE; Kang J; Liu Q; Qi J
Theranostics; 2020; 10(21):9808-9829. PubMed ID: 32863961
[No Abstract] [Full Text] [Related]
13. Zwitterionic carbon dot-encapsulating pH-responsive mesoporous silica nanoparticles for NIR light-triggered photothermal therapy through pH-controllable release.
Ryplida B; Lee G; In I; Park SY
Biomater Sci; 2019 May; 7(6):2600-2610. PubMed ID: 30984942
[TBL] [Abstract][Full Text] [Related]
14. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
Yan Y; Fu J; Wang T; Lu X
Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
[TBL] [Abstract][Full Text] [Related]
15. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
16. Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy.
Nguyen TL; Choi Y; Kim J
Adv Mater; 2019 Aug; 31(34):e1803953. PubMed ID: 30417454
[TBL] [Abstract][Full Text] [Related]
17. Extra-Large Pore Mesoporous Silica Nanoparticles for Directing in Vivo M2 Macrophage Polarization by Delivering IL-4.
Kwon D; Cha BG; Cho Y; Min J; Park EB; Kang SJ; Kim J
Nano Lett; 2017 May; 17(5):2747-2756. PubMed ID: 28422506
[TBL] [Abstract][Full Text] [Related]
18. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
[No Abstract] [Full Text] [Related]
19. Biodegradable Hollow Mesoporous Silica Nanoparticles for Regulating Tumor Microenvironment and Enhancing Antitumor Efficiency.
Kong M; Tang J; Qiao Q; Wu T; Qi Y; Tan S; Gao X; Zhang Z
Theranostics; 2017; 7(13):3276-3292. PubMed ID: 28900509
[TBL] [Abstract][Full Text] [Related]
20. HMGN1 and R848 Synergistically Activate Dendritic Cells Using Multiple Signaling Pathways.
Alam MM; Yang D; Trivett A; Meyer TJ; Oppenheim JJ
Front Immunol; 2018; 9():2982. PubMed ID: 30619338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
